摘要
替诺福韦是目前第一个被FDA批准用于治疗HIV-1感染的核苷酸类似物,属于核苷酸类逆转录酶抑制剂。本文以替诺福韦相关的专利申请文献为基础,对其结构衍进、专利技术发展脉络以及专利到期情况进行梳理分析,为相关研究者以及企业在替诺福韦的研究以及开发方面提供参考。
Tenofovir is currently the first nucleotide analogue approved by the FDA for the treatment of HIV-1 infection and belongs to the class of nucleotide reverse transcriptase inhibitors.Based on the patent application literature related to tenofovir,this paper analyzes its structural evolution,patent technology development and patent expiration,and provides reference about research and development of tenofovir for related researchers and enterprises.
作者
马永涛
万玥
张子浩
芦婷
Ma Yong-tao;Wan Yue;Zhang Zi-hao;Lu Ting(Patent Examination Cooperation Center of the Patent Office,CNIPA,Tianjin 300304)
出处
《江西化工》
2019年第3期133-136,共4页
Jiangxi Chemical Industry
关键词
替诺福韦
结构衍进
专利技术发展脉络
tenofovir
structural evolution
patent technological development
